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Methods: Prospective screening of individuals visiting
Apollo Sugar Clinics for doctor consultation from June – August
2018. The screening and risk scoring was done using a mobile tab
with DEAR app prior to doctor consultation. The scoring and
classification of risk such as no (0–8), low (9–12), medium (13–
16), high (17–20) and severe risk (21–25) were defined consid-
ering the standard ADA guidelines.
Results: Nearly 70% (2707/3867) of the patients were at me-
dium to severe risk. The severity of score increased with increasing
age (>65 years), BMI (>30 kg/m2), disease duration (>5 years),
type of medication(oral and insulin) and HbA1c (>9%). 42% of the
patients had at least one of the following complications-lipid,
kidney, eye, or foot. Lipid abnormality was the most common with
respect to age, BMI, HbA1c. Further, medium to severe risk per-
centages was higher in oral+insulin medication group compared to
only oral medication.
Conclusion: The scoring obtained enables the healthcare
professionals for thorough investigations and can also serve as an
early indicator for appropriate diabetes management program to
achieve glycemic, blood pressure and lipid targets to delay
complications for better patient outcomes. Patients with higher
risk score can be educated appropriately by a health care team.
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DECREASE IN GLYCEMIC VARIABILITY FOR T2D
OVER SIX MONTHS IN PATIENTS MONITORING
WITH A DIGITAL DIABETES MANAGEMENT
SYSTEM
Y. Hershcovitz1, E. Feniger1, S. Dar2
1Dario Health, r&d, Caesarea, Israel
2Dario Health, marketing, Caesarea, Israel
High glycemic variability (GV) is a key risk factor in the
presence of Diabetes. Frequent glucose fluctuations may not only
contribute to increasing the average blood glucose, but also fa-
vors the development of chronic diabetes complications. Dar-
ioTM Blood Glucose Monitoring System, a digital Diabetes
management system, may assist patients to reduce average gly-
cemic levels and hyperglycemia events while simultaneously
avoiding hypoglycemia.
A retrospective data evaluation study was performed on the
DarioTM database. A population of T2D high-risk patients (blood
glucose measurements average (GMavg) >180 mg/dL) measuring
more than 20 times in the first 30 days (analysis baseline) was
evaluated on days 60–90 (3 months) and 150-180 days
(6 months). Standard deviation (SD) and GMavg were calculated
and compared to the baseline.
A group of 698 T2D high-risk DarioTM users was selected. GV
was reduced by 10% and 14% from baseline through 3 and 6
months, respectively (SD of 55.7, 58.4 vs.65.0). GMavg was re-
duced by 8% and 12% from baseline through 3 and 6 months,
respectively (201.1 – 25.57, 192.8 – 54.3 vs. 219.5 – 38.5) while
patient’s hypoglycemic event (<70mg/dL) was in average, less
than one (<1) during this period. Subgroup analyses (355 patients)
revealed substantial GV improvement among non-Insulin T2D
patients. The GV was reduced by 14% and 18% from baseline
through 3 and 6 months, respectively (SD of 52.8, 50.7 vs.61.7).
To conclude: Patients using a digital Diabetes management
platform have the potential to promote behavioral modification
and enhance adherence to diabetes management, demonstrating
better glycemic control.
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RANKING PHYSIOLOGICAL, LIFESTYLE AND
ENVIRONMENTAL RISK FACTORS FOR
PREDICTING TYPE 2 DIABETES ONSET
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J. Pagán2, D. Siscovick3, B. Di Camillo1
1University of Padova, Department of Information Engineering,
Padova, Italy
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Objective: Type 2 diabetes (T2D) arises from the interaction
of physiological, lifestyle and environmental risk factors. Nu-
merous models, using different variables, were proposed in the
literature to identify subjects at risk of developing T2D. To assess
the relative importance of different risk factors, we developed a
variable ranking strategy and applied it on the Multi-Ethnic Study
of Atherosclerosis (MESA) dataset, including anthropometric
measures, fasting glucose values, co-morbidities, lifestyle and
environmental factors.
Method: A Cox model coupled with LASSO (COX-LASSO)
was trained on 4,124 subjects from the MESA dataset to predict
the time until incident T2D. COX-LASSO was trained in a Monte
Carlo bootstrap resampling scheme with B = 100 training/test
splits. The Recursive Feature Elimination algorithm was used
to rank variables within each bootstrap sample. Then, a global
ranked list was derived ordering the variables according to their
average ranking in the B resulting lists. COX-LASSO perfor-
mance was assessed on the other 1,031 subjects from the MESA
dataset by the Area Under the ROC curve (AU-ROC) at 10 years.
Results: COX-LASSO reaches performance comparable or
superior to the other existing models (AU-ROC = 0.91). The top
12 predictive variables selected by the model are, ranked by
importance: fasting glucose, HDL, waist circumference, T2D
family history, alcohol use, ethnicity, noise and lack of parks in
the neighbourhood, antidepressants use, occupation, blood pres-
sure, and hypertension.
Conclusion: Our approach highlights the importance of en-
vironmental variables to predict T2D onset. Interestingly, our
model also selected depression, which is related to T2D but is not
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Objective: Estimate the use of CGM in a Pediatric Diabetes
Unit from a Spanish region. To find out differences between the
different CGM systems (included flash type or intermittent) and
according to the type of treatment. To analyze the metabolic
control, frequency of mild and severe hypoglycaemia among the
same patients before and after using CGM and to compare pa-
tients with and without CGM.
Methods: Data are collected from September to December
2017, from patients whose diagnosis was between 2003 and 2017.
Patients are grouped in age groups (<5; 6–10;> 10) and demo-
graphic, metabolic control and treatment variables are collected.
Results: 120 patients collaborated, implying a response of
80%.70% use MDI, of which 48% use CGM, being 89% in the
case of patients using CSII. In older than 10 years there is a
predilection for intermittent measurement systems, unlike those
under 5 years prefer continuous measurement. The use of CGM
significantly reduces HbA1c compared to those who do not use
them and significantly reduces the number of mild hypoglycae-
mia, with the disappearance of severe hypoglycaemia in 6
months. 43% of patients reduce the number of glycemias/day
significantly after 6 months of use. CGM decreases almost a 5%
the HbAc1 value and a 19% the Coefficient of Variation.
Conclusion: There exists an improvement in the metabolic
control and the glycemic variability of using CGM. Hypoglycemia
is diminished by GCM, to a greater extent by the Integrated sensor-
augmented pump system. Adolescents prefer to use intermittent




THE IMPACT OF PHYSICAL EXERCISE ON SENSOR
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Background and Aims: To evaluate the sensor performance
of the Abbott Freestyle Libre intermittently-viewed continuous
glucose monitoring (iCGM) system to reference blood glucose
levels during moderate-intensity exercise while on either full or
reduced basal insulin dose in people with type 1 diabetes (T1D).
Method: Ten participants with T1D (4 females, age 32.1 – 9.0
years, BMI 25.5 – 3.8 kg/m2, HbA1c 7.2 – 0.6% (55 – 7 mmol$
mol-1)) exercised on a cycle ergometer for 55 min at a moderate
intensity for five consecutive days at the clinical research facility, on
either a usual or a 75% basal insulin dose. After a four-week wash-
out period, participants performed the second exercise period with
the remaining allocation. During exercise reference capillary blood
glucose values were analysed by fully enzymatic-amperometric
method and compared to the referring interstitial glucose values.
iCGM accuracy was analysed by median absolute relative differ-
ence (MARD (interquartile range)), Clarke error grid and Bland-
Altman analysis for overall glucose levels during exercise, stratified
for glycaemic ranges and basal insulin dosing scheme (p < 0.05).
Results: 845 glucose values were available during exercise to
evaluate iCGM sensor performance. The overall MARD across
the glycaemic range was 22%(13.9–29.7%), 36.3%(24.2–45.2%)
during hypoglycaemia, 22.8%(14.6–30.6%) during euglycaemia
and 15.4%(9–21%) during hyperglycaemia. A usual basal insulin
dose was associated with a decreased sensor performance during
exercise compared to the reduced basal insulin period (MARD:
23.7%(17.2–30.7%) vs. 20.5%(12–28.1%), p < 0.001).
Conclusion: The iCGM sensor showed diminished accuracy
during exercise. Absolute glucose readings derived from the
iCGM sensor should be used cautiously and need confirmation




COST EFFECTIVENESS OF REAL-TIME
CONTINUOUS GLUCOSE MONITORING COMPARED
WITH SELF-MONITORING OF BLOOD GLUCOSE
FOR TYPE 1 DIABETES PATIENTS IN THE UNITED
KINGDOM
M. Minshall1, D. Rentoul2, C. Graham2, J. Isitt2, B. Klinkenbijl2
1Analytica-Laser- a Certara Company, Health Economics and
Outcomes Research, New York, USA
2Dexcom- Inc., Global Access, San Diego, USA
Background: The study was designed to estimate the economic
value of a new generation rt-CGM (lasts 10 days, no calibration or
SMBG, optional receiver) compared with self-monitoring of blood
glucose (SMBG). Our analysis used the new Type 1 Diabetes
(T1D) Consensus Guideline framework (Diabetes UK, 2018) and
complication costs specific to the United Kingdom (UK).
Methods: A published and validated economic model was
used to assess the long-term (50-year) cost-effectiveness of rt-
CGM compared to SMBG for UK patients with T1D. All as-
sumptions were based on published evidence with preference for
randomized controlled trials when feasible, followed by other
published literature on complications and costs (£2018). Key base
case assumptions included: 1) starting HbA1c >8.5%; 2) change in
HbA1c: -1.29% (rt-CGM), -0.53% (SMBG); 3) rates for non-
severe hypoglycemic events (NSHEs), severe hypoglycemic
events not requiring medical assistance (SHE1) and those severe
hypoglycemic events requiring medical assistance (SHE2). Costs
and clinical outcomes were discounted at 3.5% per year.
Results: Base case incremental cost-effectiveness ratio
(ICER) for rt-CGM compared with SMBG was £3,976/QALY.
Sensitivity analyses performed under shorter time horizons, in-
creasing NSHE, SHE1 and SHE2 hypoglycemia rates for rt-
CGM, and reducing all hypoglycemia disutility rates resulted in
ICERs ranging from £3,584/QALY to £22,162/QALY. All
ICERs in our analyses were within or very close to the £20,000/
QALY threshold attributed to NICE for the UK.
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